01364nas a2200289   4500000000100000008004100001260001300042653001200055653002700067653003000094653001100124653001200135653000900147653002400156653001500180653001400195653001500209653001300224100001400237700001200251245016200263856004100425300001000466490000700476520057700483022001401060       1993                            d  c1993 Jun10aAnimals10aDisease Models, Animal10aDrug Therapy, Combination10aFemale10aleprosy10aMice10aMice, Inbred BALB C10aMice, Nude10aOfloxacin10aQuinolones10aRifampin1 aTomioka H1 aSaito H00aTherapeutic efficacy of some new quinolones and a combination of ofloxacin with rifampin against Mycobacterium leprae infection induced in athymic nude mice.  uhttp://ila.ilsl.br/pdfs/v61n2a10.pdf  a250-40 v613 a<p>Ofloxacin (OFLX), having superior antileprosy activity among the various quinolones, was studied for its combined therapeutic efficacy with rifampin (RMP) against Mycobacterium leprae infection induced in nude mice. When OFLX (3 mg/mouse) was given to infected mice in combination with RMP (0.01 mg/mouse) by gavage once daily six times per week, from day 31 to day 80 postinfection, a significant combined effect was observed. This study demonstrates the possibility of using OFLX in multidrug regimens for the clinical control of bacilliferous leprosy patients.</p>
  a0148-916X